Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with tisagenlecleucel in a real-world...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood Adv
Huvudupphovsmän: Pasquini, Marcelo C., Hu, Zhen-Huan, Curran, Kevin, Laetsch, Theodore, Locke, Frederick, Rouce, Rayne, Pulsipher, Michael A., Phillips, Christine L., Keating, Amy, Frigault, Matthew J., Salzberg, Dana, Jaglowski, Samantha, Sasine, Joshua P., Rosenthal, Joseph, Ghosh, Monalisa, Landsburg, Daniel, Margossian, Steven, Martin, Paul L., Kamdar, Manali K., Hematti, Peiman, Nikiforow, Sarah, Turtle, Cameron, Perales, Miguel-Angel, Steinert, Patricia, Horowitz, Mary M., Moskop, Amy, Pacaud, Lida, Yi, Lan, Chawla, Raghav, Bleickardt, Eric, Grupp, Stephan
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2020
Ämnen:
Immunobiology and Immunotherapy
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656920/
https://ncbi.nlm.nih.gov/pubmed/33147337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003092
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk